[AKER] Akers Biosciences Inc
Overview
Type of security: Stock
Sector: Health Care
Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances
Market Capitalization: 13.55 M
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For AKER
AKER is in the long-term down -90% below S&P in 9 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Akers Biosciences, Inc., together with its subsidiaries, focuses on the development and sale of disposable diagnostic testing devices to facilitate time sensitive therapeutic decisions in the United States and internationally. The company offers BreathScan/CHUBE, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor weight loss; VIVO for the measurement of biological markers for oxidative stress that relates to cellular damage non-invasively; PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid assay for detecting heparin-induced thrombocytopenia antibodies; seraSTAT, a device to separate rapid blood cells; and Tri-Cholesterol ?Check? to estimate high density lipoprotein cholesterol and low density lipo protein levels. It is also involved in the development of Breath Ketone ?Check?, a disposable breath ketone device for diabetic monitoring, and management of senile dementia and alzheimers disease patients; Breath PulmoHe
See how to gain 20% in 14 sec with TrendsInvesting
Fundamental Ratios
| Shares Outstanding | 5.42 M | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | |||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | -62.31% | Sales Growth - Q/Q | -64.75% | P/E | ||
| P/E To EPS Growth | P/S | 3.6 | P/BV | 0.95 | Price/Cash Per Share | 1.61 | |
| Price/Free Cash Flow | -3.47 | ROA | -25.08% | ROE | -27.12% | ROI | |
| Current Ratio | 10.26 | Quick Ratio | 9.42 | Long Term Debt/Equity | Debt Ratio | 0.08 | |
| Gross Margin | 78.85% | Operating Margin | -105% | Net Profit Margin | -102.39% | Dividend Payout Ratio | |
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | Cash From Investing Activities | Cash From Operating Activities | 1.12 M | Gross Profit | 280 K | ||
| Net Profit | -1.24 M | Operating Profit | -1.36 M | Total Assets | 15.36 M | Total Current Assets | 11.81 M |
| Total Current Liabilities | 1.15 M | Total Debt | Total Liabilities | 1.15 M | Total Revenue | 510 K |
Technical Data
| High 52 week | 3.76 | Low 52 week | 0.13 | Last close | 1.47 | Last change | 13.08% |
| RSI | 77.33 | Average true range | 0.22 | Beta | 1.44 | Volume | 16.56 K |
| Simple moving average 20 days | 32.34% | Simple moving average 50 days | -3.02% | Simple moving average 200 days | 22.91% |
Performance Data
| Performance Week | 2.08% | Performance Month | 26.72% | Performance Quart | -50.34% | Performance Half | 208.69% |
| Performance Year | 91.16% | Performance Year-to-date | 30.09% | Volatility daily | 12.57% | Volatility weekly | 28.11% |
| Volatility monthly | 57.61% | Volatility yearly | 199.57% | Relative Volume | 179.39% | Average Volume | 2.17 M |
| New High | New Low |
News
2020-05-29 14:22:44 | Hedge Funds Are Nibbling On Akers Biosciences Inc AKER
2020-05-18 17:33:39 | Akers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
2020-05-14 14:01:00 | Microcap Akers Biosciences Spikes on Covid-Vaccine Progress
2020-05-14 13:00:10 | Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
2020-05-14 09:33:11 | Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP
2020-04-24 10:19:00 | Here's How Akers Biosciences and Premas Biotech Plan To Knock Out COVID-19 Virus; Company Halfway Through Four Milestone Plan
2020-04-09 11:01:49 | Akers Biosciences plans $4.6M stock sale, advances COVID-19 vaccine candidate
2020-04-08 11:10:33 | Akers Says It's Halfway Through Plan To Develop COVID-19 Vaccine Candidate
2020-04-08 09:25:10 | Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens
2020-04-07 10:53:34 | Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
2020-04-06 09:25:10 | Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19
2020-03-24 17:14:59 | South Jersey company's stock closes up 22% after coronavirus vaccine deal
2020-03-24 17:14:59 | South Jersey company's stock closes up 22% after coronavirus vaccine deal
2020-03-24 16:06:25 | Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate
2020-03-24 09:00:10 | Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech
2020-01-17 17:00:10 | Akers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation
2019-12-11 09:30:10 | Akers BioSciences Regains Compliance with Nasdaq Listing Standards
2019-12-10 11:30:00 | Akers Biosciences to Present at the Investor Summit on December 17th in Philadelphia
2019-12-09 11:40:10 | Akers BioSciences, Inc. Announces Closing of Approximately $8 Million Public Offering
2019-12-06 09:30:10 | Akers Biosciences to Attend Hemp Industry Daily Forum in Las Vegas, Nevada
2019-12-06 07:39:38 | The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
2019-12-05 16:55:54 | South Jersey medical device maker raising $8M through stock offering
2019-12-05 09:25:10 | Akers BioSciences, Inc. Announces Pricing of Approximately $8 Million Public Offering
2019-12-05 08:45:10 | Akers Biosciences Continues Strategic Review; Explores Leveraging its 30-years of Laboratory Operations to Enter into the Hemp and Minor Cannabinoid Processing Industry
2019-11-22 09:15:10 | Akers Biosciences, Inc. Announces One-for-Twenty Four Reverse Stock Split
2019-09-25 15:15:00 | AKER: Final Settlement Hearing Rescheduled to December 20, 2019
2019-08-15 09:00:00 | Akers Biosciences Reports Q2 2019 Earnings
2019-08-05 14:29:27 | Local companies impacted by trade war-fueled stock market decline
2019-07-29 08:00:00 | The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Akers Biosciences, Inc. Common Stock -- AKER
2019-07-09 08:03:59 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.
2019-06-10 08:04:31 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.
2019-05-20 17:38:54 | Akers Biosciences Reports Q1 2019 Earnings
2019-04-02 14:15:30 | As losses mount, medical device maker continues pursuit of 'strategic alternatives'
2019-04-01 17:31:34 | Akers Biosciences Reports Fiscal Year 2018 Earnings
2019-03-28 08:02:46 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.
2019-02-19 08:01:57 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.
2019-02-16 08:05:31 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.
2019-02-08 08:05:39 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.
2019-02-05 08:05:45 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.
2019-01-31 08:04:57 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.
2019-01-17 08:02:09 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.
2019-01-15 08:04:54 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.
2019-01-09 08:05:01 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.
2018-12-31 10:50:00 | 4 Healthcare Stocks That Are Raising Eyebrows
2018-12-28 11:45:00 | These 4 Healthcare Stocks Are Heating Up
2018-11-29 08:06:42 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.
2018-11-20 15:09:56 | This Tiny Biotech Firm Is Weighing An Entrance Into Cannabis
2018-11-20 08:06:47 | See what the IHS Markit Score report has to say about Akers Biosciences Inc.